Clinical Guides
Allergic Bronchopulmonary Aspergillosis
A clinically focused guide to diagnosing and managing allergic bronchopulmonary aspergillosis in asthma, cystic fibrosis and bronchiectasis, with Indian tuberculosis differentials, precise immunological and imaging criteria, steroid and azole safety, biologic evidence limits and access-aware follow-up.
MedNext Academy | 13 min read
Allergic Bronchopulmonary Aspergillosis
A clinically focused guide to diagnosing and managing allergic bronchopulmonary aspergillosis in asthma, cystic fibrosis and bronchiectasis, with Indian tuberculosis differentials, precise immunological and imaging criteria, steroid and azole safety, biologic evidence limits and access-aware follow-up.
Summary
Allergic bronchopulmonary aspergillosis (ABPA) is an immune-mediated pulmonary disorder caused by hypersensitivity to airway-colonizing Aspergillus, usually A. fumigatus. It most often complicates asthma or cystic fibrosis but can occur with bronchiectasis or chronic obstructive lung disease, and a compatible clinico-radiological presentation can justify evaluation even without a previously labelled predisposing disease. ABPA is neither simple fungal sensitization nor invasive aspergillosis. Recurrent eosinophilic inflammation and mucus impaction can produce fleeting opacities, central or more extensive bronchiectasis, high-attenuation mucus and progressive structural damage.
The 2024 revised ISHAM criteria require a predisposing condition or compatible presentation, A. fumigatus-specific IgE at least 0.35 kUA/L and serum total IgE usually at least 500 IU/mL, plus any two of raised A. fumigatus-specific IgG, blood eosinophils at least 500 cells/µL currently or historically, and characteristic imaging. High-attenuation mucus on thin-section CT is pathognomonic and can confirm the diagnosis even when another component is absent. Results must be interpreted with assay- and population-specific cutoffs.
For acute ABPA, ISHAM recommends oral prednisolone or itraconazole monotherapy; combined treatment is reserved for selected recurrent exacerbations rather than used routinely. Treatment-dependent disease may justify long-term azole, inhaled amphotericin or a biologic after specialist review, but biologic evidence is mainly small studies and experience extrapolated from severe asthma. In India, tuberculosis and post-TB bronchiectasis are essential differentials. This quarantined educational draft has been reviewed by the MedNext Clinical Team and is not a patient-specific steroid, antifungal or biologic prescription.
How Common Is It?
ABPA prevalence depends strongly on the population screened, asthma severity, cystic-fibrosis care, diagnostic criteria, assay availability and referral setting. It is enriched in difficult-to-treat asthma and specialist bronchiectasis clinics, but population estimates cannot be transferred directly to an individual patient. The revised ISHAM group recommends screening adults with asthma for A. fumigatus sensitization in tertiary care because missed disease can lead to bronchiectasis and fibrosis; universal screening across every low-resource primary-care setting was not supported by the same evidence. Children are generally screened when asthma is difficult to treat rather than automatically.
Indian referral centres have contributed substantially to the ABPA evidence base, including the 2024 international guideline, but that does not establish one current national prevalence. Case detection varies with access to specific IgE, quantitative total IgE, Aspergillus IgG and thin-section CT. Using the older 1,000 IU/mL total-IgE threshold misses some cases, while indiscriminate testing in people with low pre-test probability produces sensitization results without disease. Steroid exposure can also reduce eosinophils and total IgE.
The clinical burden is better expressed as preventable exacerbations, mucus plugging, lung collapse, bronchiectasis, haemoptysis and, in advanced cases, chronic respiratory failure rather than as one headline percentage. India also has a high tuberculosis burden and substantial post-TB structural lung disease, creating both genuine coexistence and diagnostic misclassification. Local audits should state the denominator, criteria, assays and referral mix. For bedside care, apply the full diagnostic framework and longitudinal response rather than quoting a prevalence number as proof.
Risk Factors
The principal susceptibility states are asthma and cystic fibrosis, with bronchiectasis and COPD now recognized within the revised diagnostic framework. Poorly controlled or severe asthma raises suspicion but does not itself diagnose ABPA. Fungal sensitization, impaired mucociliary clearance, thick mucus and structurally abnormal airways allow persistent antigen exposure. Atopy and eosinophilic inflammation are common. Environmental Aspergillus spores are ubiquitous, so routine household exposure is neither necessary nor sufficient; a positive sensitization test cannot identify a particular building as the cause.
Clinical clues include recurrent exacerbations despite appropriate inhaled therapy, expectoration of brownish or tenacious plugs, fleeting or migratory pulmonary opacities, lobar collapse, bronchiectasis, peripheral eosinophilia and a very high total IgE. Prior systemic corticosteroids may suppress eosinophilia and lower IgE, so a reliable historical eosinophil count can meet the criterion. High-attenuation mucus on CT identifies a particularly specific phenotype. Genetic and immune factors modify susceptibility, but current practice does not use broad genetic testing to decide routine care.
Risk of treatment toxicity also shapes management. Diabetes, hypertension, obesity, osteoporosis, glaucoma, cataract, infection risk and mood disorder increase corticosteroid harm. Liver disease, heart failure, neuropathy, drug interactions and variable absorption affect azole choice. Rifampicin profoundly reduces triazole exposure, which is crucial when tuberculosis treatment is being considered. Biologic eligibility depends on the severe-asthma phenotype and local funding, while pregnancy and childhood require additional specialist judgment. Avoiding damp or mould may improve general respiratory health, but environmental remediation cannot replace evidence-based ABPA treatment.
Diagnosis
History
Ask about established asthma, cystic fibrosis, bronchiectasis or COPD; wheeze, cough, dyspnoea, fever, haemoptysis, mucus plugs and recurrent 'pneumonia'; prior radiographic shadows; and response to corticosteroids or antifungals. Document exacerbation frequency, maintenance inhalers, adherence and technique. In India, actively seek tuberculosis exposure, previous TB, weight loss, night sweats, microbiology and treatment records. Ask about steroid and azole toxicity, liver disease, pregnancy, heart failure, neuropathy and interacting medicines, including rifamycins.
Examination
Record respiratory rate, oxygen saturation, fever and work of breathing. Wheeze is common, while crackles, bronchial breathing, reduced air entry from collapse, clubbing or signs of bronchiectasis suggest structural disease or another diagnosis. Examine for corticosteroid complications and severe-asthma comorbidity such as nasal polyps. A normal examination between exacerbations does not exclude ABPA. Haemodynamic instability, hypoxaemia or major haemoptysis requires emergency management before completing immunological criteria.
Investigations
Measure A. fumigatus-specific IgE and total IgE. With compatible disease, essential thresholds are specific IgE at least 0.35 kUA/L and total IgE usually at least 500 IU/mL; lower total IgE may be accepted when every other criterion is fulfilled. Add A. fumigatus-specific IgG using a population-specific or manufacturer cutoff, eosinophil count current or historical, and thin-section chest CT for bronchiectasis, mucus plugging and high-attenuation mucus. Obtain spirometry for airflow limitation and a baseline total IgE during clinical stability. Sputum fungal culture helps species identification and is especially important before antifungal therapy or for ABPM, but routine bronchoscopy is not recommended. Investigate TB with appropriate molecular microbiology and imaging when clinically plausible; neither CT nor IgE excludes it.
Differential Diagnosis
Aspergillus sensitization without ABPA is commoner than ABPA: specific IgE or a positive skin test alone does not establish disease. Severe asthma with fungal sensitization may cause poor control without meeting ABPA criteria. Aspergillus bronchitis is characterized by repeated airway culture and symptoms without the full allergic syndrome. Chronic pulmonary aspergillosis more often produces chronic cavities, pleural thickening or an aspergilloma in structurally damaged lung; invasive aspergillosis occurs chiefly with substantial immunosuppression and has a different urgency and treatment pathway. Allergic bronchopulmonary mycosis is considered when the syndrome is ABPA-like but A. fumigatus-specific IgE is normal and another fungus is repeatedly cultured.
Pulmonary tuberculosis is a priority Indian differential for fever, weight loss, haemoptysis, cavities, nodules or upper-lobe change. Post-TB bronchiectasis can coexist with Aspergillus sensitization, ABPA or chronic pulmonary aspergillosis. Obtain microbiological evidence rather than diagnosing TB or ABPA from imaging pattern alone. Non-tuberculous mycobacteria, bacterial bronchiectasis exacerbation, eosinophilic pneumonia, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome and drug reactions also require consideration.
Asthma exacerbation is distinguished from ABPA exacerbation by the absence of immunological or radiological worsening. An infective or bronchiectasis exacerbation causes increased cough, sputum volume or purulence, fever or malaise without the IgE rise and imaging change required for ABPA relapse. Cystic-fibrosis pulmonary exacerbation can overlap substantially. Multidisciplinary review is valuable when criteria conflict, especially after corticosteroid exposure, when CT shows cavities, or when tuberculosis and antifungal drug interactions would materially change treatment.
Management
First stabilize acute asthma, hypoxaemia, collapse, major haemoptysis or sepsis using the appropriate emergency pathway. Confirm the ABPA phenotype before prolonged therapy, optimize inhaled corticosteroid-containing asthma treatment, teach airway clearance when bronchiectasis or mucus plugging is present, update vaccination and address smoking. Bronchoscopy is reserved for selected diagnostic uncertainty or persistent mucus plugging and is not routine treatment. Environmental advice should focus on obvious heavy mould exposure and safe remediation without blaming patients for ubiquitous spores.
For newly diagnosed acute ABPA or an ABPA exacerbation, the revised ISHAM guideline recommends either a defined oral prednisolone course or oral itraconazole monotherapy. Prednisolone gives faster anti-inflammatory control; itraconazole reduces fungal burden and may be chosen when steroid toxicity is a major concern, but absorption, interactions and monitoring matter. Routine initial combination therapy adds adverse effects without clear universal benefit. Consider prednisolone plus itraconazole for recurrent exacerbations. Asymptomatic ABPA is generally not treated systemically; instead, use individualized monitoring because imaging progression or poor lung reserve may justify specialist deviation.
Reassess after about 8-12 weeks using symptoms, imaging and total IgE. A response includes major symptom or radiological improvement plus an IgE reduction of at least 20%; failure prompts adherence, exposure, diagnosis, infection and drug-level review. Remission does not require maintenance systemic therapy. Treatment-dependent ABPA may use long-term itraconazole, nebulized amphotericin or a biologic selected by a specialist. Evidence for biologics is limited, costs and access are substantial, and treatment should target both ABPA dependence and any qualifying severe-asthma phenotype.
Prescribing Information
Oral prednisolone regimens in the ISHAM table include 0.5 mg/kg/day for two weeks followed by alternate-day dosing for eight weeks, then tapering by 5 mg every two weeks to complete about four months; an alternative uses daily dosing for four weeks followed by a similar taper. These are guideline frameworks, not automatic prescriptions. Verify indication, weight, blood pressure, glucose, infection risk, bone protection, gastrointestinal risk, mood, eye disease and pregnancy. Give a written taper and sick-day advice. Abrupt cessation after prolonged therapy risks adrenal insufficiency, while repeated unsupervised bursts accumulate harm.
Conventional itraconazole capsules are generally used in divided dosing for about four months and are taken with food; formulations differ, and super-bioavailable products have different dosing and fasting instructions. Check the exact formulation, liver tests, heart-failure risk, neuropathy, pregnancy potential and interactions. Therapeutic drug monitoring is recommended because absorption is variable; ISHAM specifies a trough target of at least 0.5 mg/L for itraconazole. Proton-pump inhibitors can reduce conventional capsule absorption. Rifampicin and other potent enzyme inducers can make triazole exposure ineffective, while triazoles can raise concentrations of many corticosteroids and cardiovascular medicines.
Voriconazole, posaconazole or isavuconazole are not routine first-line substitutes; use specialist selection for intolerance, failure or resistance with formulation-specific monitoring. Biologics such as omalizumab or anti-IL-5/IL-5R and anti-IL-4R agents have steroid-sparing reports, but ABPA trial evidence remains limited and eligibility, dosing and infection precautions follow the chosen severe-asthma pathway. Inhaled amphotericin can help prevent recurrent exacerbations in selected treatment-dependent disease. Record product, dose, duration, stop criteria and review plan; never combine rifamycin and azole casually.
When to Refer
Refer to a respiratory specialist when ABPA is suspected from difficult asthma, mucus plugs, fleeting opacities, eosinophilia, high total IgE or bronchiectasis. Early referral is appropriate when the essential tests or thin-section CT are unavailable, results are discordant, total IgE is below threshold despite a compelling phenotype, ABPM is possible, or corticosteroids already distort biomarkers. Include asthma history and treatment, exacerbation timeline, all prior imaging, total and specific IgE with units and assay, eosinophil history, Aspergillus IgG method, sputum microbiology, TB results, spirometry and a complete drug list.
Urgent same-day care is needed for severe asthma, hypoxaemia, respiratory exhaustion, significant haemoptysis, sepsis, lung collapse with distress or suspected invasive fungal disease in an immunocompromised patient. Expedite specialist assessment for cavities, an aspergilloma, progressive fibrosis, pulmonary hypertension, recurrent lobar collapse, rapidly falling lung function or diagnostic concern for tuberculosis. Infectious-disease or TB consultation is important when mycobacterial disease coexists because rifamycin-azole interactions can make standard plans incompatible.
Refer to a severe-asthma or multidisciplinary bronchiectasis service before biologic therapy, maintenance antifungal treatment or repeated systemic steroid courses. Pharmacy input is valuable for therapeutic drug monitoring, interactions and access. In cystic fibrosis, coordinate with the CF team because symptoms, imaging and biomarkers overlap with pulmonary exacerbations. Where testing is unaffordable, referral should prioritize the minimum decision-changing set rather than serial empirical steroid-antifungal combinations that obscure diagnosis and create preventable toxicity.
Red Flags
Severe breathlessness, inability to speak, silent chest, cyanosis, confusion, exhaustion, hypotension or low oxygen saturation indicates life-threatening asthma or respiratory failure and overrides outpatient ABPA work-up. Major or recurrent haemoptysis requires urgent stabilization and imaging because bronchiectasis, mycetoma, tuberculosis and vascular complications may be responsible. Fever with haemodynamic instability, pleuritic pain or rapidly progressive infiltrates should not be attributed to allergic inflammation without evaluating bacterial infection, TB, embolism and invasive fungal disease.
Weight loss, drenching night sweats, persistent fever, new cavitation or known TB contact demands a tuberculosis pathway with appropriate infection control and microbiology. A positive Aspergillus test does not exclude TB. Conversely, prior TB does not explain every new opacity. Immunosuppression from corticosteroids increases infection risk, so clinical deterioration during treatment requires diagnostic reassessment rather than a reflex steroid increase. New focal neurological symptoms, visual change or disseminated signs in an immunocompromised patient raise concern for invasive disease, not routine ABPA.
Jaundice, dark urine, severe nausea, new neuropathy, oedema or worsening breathlessness may signal azole toxicity; syncope or palpitations can reflect interaction-related cardiac risk. Marked hyperglycaemia, psychosis, gastrointestinal bleeding, acute visual symptoms or adrenal crisis symptoms during steroid therapy need urgent care. Pregnancy, major liver disease and heart failure materially change drug choice. Failure of total IgE to fall, radiological progression or recurrent relapse despite apparently adequate therapy should trigger review of adherence, formulation, drug level, resistance, alternative fungal disease and the original diagnosis.
Indian Clinical Context
ABPA expertise and much of the contemporary evidence come from Indian respiratory centres, yet access to A. fumigatus-specific IgE, quantitative IgG, thin-section CT, fungal culture and therapeutic drug monitoring remains uneven. The 2024 ISHAM guideline provides an India-specific A. fumigatus IgG example cutoff of at least 27 mgA/L for the assay studied, while explicitly requiring population- and method-specific interpretation. Laboratories using another platform should not copy that number without validation. When resources are limited, confirm which result will change the decision and avoid substituting a non-standard skin or antibody panel for the full clinical framework.
Tuberculosis is a central safety issue. The India TB Report 2024 documents the continuing national programme burden and diagnostic network; it does not authorize empirical TB treatment for every upper-lobe opacity. ABPA, post-TB bronchiectasis, chronic pulmonary aspergillosis and active TB can coexist. Send appropriate sputum molecular and culture testing when indicated, retrieve previous treatment and susceptibility data, and coordinate NTEP care. Rifampicin-triazole interaction is clinically profound, so concurrent disease needs specialist pharmacological planning rather than dose guesswork.
Prednisolone and conventional itraconazole may be accessible, but monitoring costs, formulation quality, interaction review and repeated travel can still limit safe care. Biologics are expensive and their ABPA evidence is substantially weaker than their severe-asthma evidence; affordability must not be misrepresented as clinical suitability. Provide written plans in an understandable language, retain baseline IgE and CT reports, define emergency access, and use tele-follow-up only when examination or testing is not being deferred unsafely.
NMC Competency Mapping
ABPA integrates NMC undergraduate competencies in asthma, respiratory infection, bronchiectasis, eosinophilic disease, imaging interpretation, pharmacology and rational diagnostic testing. Learners should recognize when asthma control is unexpectedly poor, elicit mucus-plug and recurrent-opacity history, distinguish fungal sensitization from allergic disease and explain the essential and supporting components of the revised diagnostic criteria. They should interpret total IgE longitudinally rather than as a nonspecific one-off screening value and recognize that eosinophilia may be historical after corticosteroid exposure.
Applied learning should cover examination of an acutely breathless patient, spirometry principles, chest-radiograph patterns, the role of thin-section CT, sputum collection and microbiological evaluation for tuberculosis. A student should formulate differentials that include severe asthma with fungal sensitization, bacterial bronchiectasis exacerbation, TB, chronic pulmonary aspergillosis, eosinophilic pneumonia and vasculitis. The Indian context requires awareness of NTEP referral and of unequal access to immunological assays and drug-level monitoring.
Pharmacology competencies include systemic corticosteroid adverse effects and tapering, triazole absorption, hepatotoxicity, heart-failure caution, therapeutic drug monitoring and major enzyme interactions, especially rifampicin. Evidence-based practice includes explaining why routine combination therapy and biologics are not universal first-line choices. Practical competence requires supervised history, examination, inhaler teaching and test interpretation; this guide does not certify independent biologic selection, bronchoscopy, antifungal prescribing or management of severe asthma. Institutions should map these outcomes to the current 2024 CBME document rather than rely on an unverified legacy code list.
Key Exam Pearls for NEET PG
ABPA is a hypersensitivity disorder from airway colonization, classically in asthma or cystic fibrosis; it is not tissue-invasive aspergillosis. Revised essential components are A. fumigatus-specific IgE at least 0.35 kUA/L and total IgE at least 500 IU/mL in an appropriate clinical setting. Add any two: A. fumigatus-specific IgG, eosinophils at least 500 cells/µL currently or historically, and compatible imaging. High-attenuation mucus is pathognomonic. Central bronchiectasis, finger-in-glove mucus impaction and fleeting opacities are classic but none alone replaces the criteria.
An ABPA exacerbation requires sustained clinical or radiological worsening, a total-IgE increase of at least 50% from the stable baseline and exclusion of other causes. Asthma exacerbation lacks immunological or radiological ABPA deterioration; bronchiectasis infection produces sputum and systemic change without the ABPA pattern. Treatment response after about 8-12 weeks includes symptom or radiological improvement plus at least a 20% IgE reduction. The new stable IgE becomes the baseline; IgE need not normalize.
Acute disease is treated with oral prednisolone or itraconazole monotherapy; combine them mainly for recurrent exacerbations. Do not routinely treat asymptomatic disease or give systemic antifungal treatment for sensitization alone. Remember itraconazole therapeutic drug monitoring, hepatic and cardiac toxicity and potent interactions. Rifampicin reduces azole concentrations, making TB co-management critical. Biologics may spare steroids in treatment-dependent disease, but evidence is limited and specialist selection is required.
Frequently Asked Questions
Does a positive Aspergillus-specific IgE test mean that a patient has ABPA?
No. It establishes sensitization, which is an essential component but can occur without ABPA. Diagnosis also needs the appropriate clinical setting, usually a total IgE of at least 500 IU/mL, and supporting IgG, eosinophil or imaging criteria. Severe asthma with fungal sensitization and other Aspergillus syndromes require different management.
Why is total IgE repeated during treatment and follow-up?
Total IgE is a longitudinal activity marker rather than a stand-alone diagnostic test. A fall of at least 20% supports treatment response when accompanied by clinical or imaging improvement. During stability, the new value becomes the reference; a rise of at least 50% plus sustained clinical or radiological worsening supports exacerbation after other causes are excluded.
Can tuberculosis and allergic bronchopulmonary aspergillosis occur together?
Yes. Active TB, post-TB bronchiectasis, ABPA and chronic pulmonary aspergillosis can coexist and share symptoms or imaging features. In India, weight loss, fever, haemoptysis or cavitation warrants appropriate TB microbiology. Drug planning needs specialist input because rifampicin markedly lowers triazole exposure, while corticosteroids can worsen unrecognized infection.
Are biologic medicines the best first treatment for every case of ABPA?
No. Oral prednisolone or itraconazole monotherapy is the recommended initial approach for acute ABPA. Biologic evidence in ABPA is mainly from small studies and extrapolation from severe asthma. A biologic may be considered for treatment-dependent disease or a qualifying severe-asthma phenotype after adherence, infection, bronchiectasis care, costs, access and monitoring have been reviewed.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic